Bio-Rad Laboratories, a manufacturer of life science research products, has entered into an agreement to acquire QuantaLife for $162m.
QuantaLife has developed a digital Polymerase Chain Reaction (PCR) system which provides quantification of target molecules and is built on the method of amplifying DNA that is used in research laboratories.
Digital PCR aids researchers with a new tool which is used for the detection of rare mutations including absolute quantification of gene expression, precise measurement of copy number variation and distinguishing rare sequences in tumors.
Bio-Rad president and CEO Norman Schwartz said this solution expands the current methods of quantitative PCR (qPCR), and they look forward to its adoption in life science research.